Onward Medical N.V. (EBR:ONWD)
Belgium
· Delayed Price · Currency is EUR | Market Cap | 200.59M |
| Revenue (ttm) | 5.41M |
| Net Income (ttm) | -41.79M |
| Shares Out | 69.53M |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 121,353 |
| Average Volume | 249,150 |
| Open | 2.885 |
| Previous Close | 2.885 |
| Day's Range | 2.790 - 2.885 |
| 52-Week Range | 2.655 - 5.770 |
| Beta | 0.98 |
| RSI | 32.75 |
| Earnings Date | Mar 31, 2026 |
About Onward Medical
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people with SCI; ARCBCI, an implanted brain-computer interface to restore thought-driven movement. It operates in France, Germany, the Netherlands, the United Ki... [Read more]
Financial Performance
In 2025, Onward Medical's revenue was 5.41 million, an increase of 211.33% compared to the previous year's 1.74 million. Losses were -41.79 million, 17.0% more than in 2024.
Financial StatementsNews
ONWARD Medical Publishes Closing of Bookbuild Offering
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHE...
ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 40 Million
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHE...
ONWARD Medical Publishes Convocation of the 2026 Annual General Meeting of Shareholders and Proposed Resolutions
EINDHOVEN, the Netherlands, April 01, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, funct...
Onward Medical NV (ONWRF) Full Year 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Onward Medical NV (ONWRF) Full Year 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Expenses
Full Year 2025 ONWARD Medical NV Earnings Call & Business Update Transcript
Full Year 2025 ONWARD Medical NV Earnings Call & Business Update Transcript
Onward Medical Earnings Call Transcript: Q4 2025
Achieved rapid U.S. market penetration with 117 ARC-EX systems sold, EUR 5.4M in revenue, and major regulatory milestones. Raised over EUR 50M, advanced pivotal studies, and set the stage for accelerated growth and potential Nasdaq IPO.
ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD Medical Schedules Webcast to Report Full-Year 2025 Financial Results and Provide Business Update
EINDHOVEN, the Netherlands, March 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, funct...
ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury
EINDHOVEN, the Netherlands, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to rest...
ONWARD Medical Completes Two Additional Brain-Computer Interface Implants Paired with Spinal Cord Stimulation Technology to Restore Thought-Driven Movement
EINDHOVEN, the Netherlands, Jan. 22, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore ...
Onward Medical Transcript: Life Sciences Virtual Investor Forum 2025
Innovative spinal cord stimulation platforms are advancing through commercialization and clinical trials, with strong early sales, robust clinical evidence, and strategic funding. Key milestones include expanding sales, pivotal trial progress, and new device launches in the next year.
Onward Medical Earnings Call Transcript: Q3 2025
Q3 revenue reached EUR 1.7 million with strong U.S. clinic adoption and high device utilization. Regulatory milestones and a EUR 50 million capital raise support European and home use expansion, with robust demand and a solid cash position.
ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important Scientific and Regulatory Milestones in Q3 2025
EINDHOVEN, the Netherlands, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, functi...
ONWARD Medical Receives FDA 510(k) Clearance Expanding ARC-EX System Indication for Home Use
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHE...
ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating ARC-EX Adoption in the United States
EINDHOVEN, the Netherlands, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, functi...
Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical with a Buy Rating and Target Price of EUR 10.20
EINDHOVEN, the Netherlands, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, functi...
Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy
EINDHOVEN, The Netherlands, Sept. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, funct...
ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch of Breakthrough Spinal Cord Stimulation System in Europe
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
Onward Medical Earnings Call Transcript: Q2 2025
Strong H1 2025 commercial traction for ARC-EX with 30 units sold and robust clinic demand; cash position of €40.9M supports pipeline and pivotal Empower BP study launch. Regulatory milestones and sales acceleration expected in H2, with focus on disciplined cost management.
ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors
EINDHOVEN, The Netherlands, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, fu...
ONWARD Medical Adds Entrepreneur and Neurotechnology Thought Leader Tim Denison, PhD to its Board of Directors
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)